Photodynamic therapy (
PDT) is a Food and Drug Administration authorized method for
cancer treatment, which uses
photosensitizer and
laser photo-irradiation to generate
reactive oxygen species to induce cell death in
tumors.
Photosensitizers have been progressively developed, from first to third generation, with improvements in cell specificity, reduced side effects and toxicity, increased sensitivity for irradiation and reduced persistence of
photosensitizer in healthy cells. These improvements have been achieved by basic comparative experiments between current and novel
photosensitizers using cell lines; however,
photosensitizers should be carefully evaluated because they may have cell type specificity. In the present study, we compared a third-generation
photosensitizer, β-
mannose-conjugated
chlorin (β-M-
chlorin), with the second generation,
talaporfin sodium (
NPe6), using seven different rat and human cell lines and a neuronal/glial primary culture prepared from rat embryos.
NPe6 was more effective than β-M-
chlorin in human-derived cell lines, and β-M-
chlorin was more effective than
NPe6 in rat primary cultures and rat-derived cell lines, except for the rat pheochromocytoma cell line, PC12. These differences of
phototoxicity in different cell types are not because of differences in photosensitivity between the
photosensitizers, but rather are associated with different distribution and accumulation rates in the different cell types. These data suggest that evaluation of
photosensitizers for
PDT should be carried out using as large a variety of cell types as possible because each
photosensitizer may have cell type specificity.